Skip to content
Catalyst

rosuvastatinWhat was measured

Measured, with no finding

251 endpoints

Show what was measuredHide what was measured
  • 5-year NNT to prevent 1 primary endpoint

    The 5-year NNT to prevent 1 primary endpoint was calculated at 36 in women, 22 in men, and 25 when combined

    PMID 20176986 · one of two readings recorded this

  • 5-year NNT to prevent 1 primary endpoint

    The 5-year NNT to prevent 1 primary endpoint was calculated at 36 in women, 22 in men, and 25 when combined

    PMID 20176986 · one of two readings recorded this

  • All-cause death (hazard ratio)

    no effect

    The HR for all cause death was similarly reduced for women (HR 0.77, 95% CI 0.55–1.06) and men (HR 0.82, 95% CI 0.66–1.03)

    PMID 20176986 · one of two readings recorded this

  • All-cause death (hazard ratio)

    no effect

    The HR for all cause death was similarly reduced for women (HR 0.77, 95% CI 0.55–1.06) and men (HR 0.82, 95% CI 0.66–1.03)

    PMID 20176986 · one of two readings recorded this

  • Baseline hsCRP

    unclear, p = 0.001

    Women had higher concentrations of hsCRP (4.6 vs 4.1 mg/L, respectively, P<0.001)

    PMID 20176986 · one of two readings recorded this

  • Baseline LDL cholesterol

    no effect

    Women and men had similar baseline LDL cholesterol (109 and 108 mg/dL, respectively)

    PMID 20176986 · one of two readings recorded this

  • CVD events, statin trials in women (meta-analysis, relative risk)

    decreases, p = 0.001, n = 13154

    The summary RR for the 3 trials was 0.63 (0.49–0.82), P<0.001, P for heterogeneity 0.56

    PMID 20176986 · one of two readings recorded this

  • CVD events, statin trials in women (meta-analysis, relative risk)

    decreases, p = 0.03

    the summary RR was unchanged (0.82, 95% CI 0.69–0.98), P=0.03

    PMID 20176986 · one of two readings recorded this

  • CVD events, statin trials in women (meta-analysis, relative risk)

    no effect, p = 0.11

    the summary RR was similar but not statistically significant, 0.79 (95% CI 0.59–1.05), P=0.11, P for heterogeneity=0.053

    PMID 20176986 · one of two readings recorded this

  • HDL cholesterol change

    increases

    HDL cholesterol increased by 3 mg/dL and 1 mg/dL in women on rosuvastatin and placebo, respectively

    PMID 20176986 · one of two readings recorded this

  • hsCRP median change

    decreases

    At 12-month follow-up, the median change in hsCRP concentrations in women was −1.8 mg/L (39%) with rosuvastatin and −0.6 mg/L (13%) with placebo

    PMID 20176986 · one of two readings recorded this

  • LDL cholesterol median change

    decreases

    In women, the median change in LDL cholesterol was −51 mg/dL (47%) on rosuvastatin and +4 mg/dL (4%) on placebo

    PMID 20176986 · one of two readings recorded this

  • Physician-reported diabetes

    no effect, p = 0.24

    compared with men (1.36 vs 1.20 per 100 person-years, respectively, HR 1.14, 95% CI 0.91–1.43, P=0.24)

    PMID 20176986 · one of two readings recorded this

  • Physician-reported diabetes

    increases, p = 0.008

    a higher incidence of physician-reported diabetes was observed in women treated with rosuvastatin vs placebo (1.53 vs 1.03 per 100 person-years, respectively, HR 1.49, 95% CI 1.11–2.01, P=0.008)

    PMID 20176986 · one of two readings recorded this

  • Primary composite CVD endpoint absolute rate

    decreases

    the absolute rates (per 100 person-years) of the primary endpoint in rosuvastatin and placebo were lower in women (0.56 and 1.04, respectively) than men (0.88 and 1.54, respectively)

    PMID 20176986 · one of two readings recorded this

  • Primary composite CVD endpoint absolute rate

    decreases

    the absolute rates (per 100 person-years) of the primary endpoint in rosuvastatin and placebo were lower in women (0.56 and 1.04, respectively) than men (0.88 and 1.54, respectively)

    PMID 20176986 · one of two readings recorded this

  • Primary composite CVD endpoint (hazard ratio)

    decreases, p = 0.001, n = 11001

    and men (0.58, 95% CI 0.45–0.73, P<0.001

    PMID 20176986 · one of two readings recorded this

  • Primary composite CVD endpoint (hazard ratio)

    decreases, p = 0.002, n = 6801

    the relative risk reduction with rosuvastatin was similar and statistically significant in both women (hazard ratio 0.54, 95% CI 0.37–0.80, P=0.002)

    PMID 20176986 · one of two readings recorded this

  • Primary endpoint absolute rate

    decreases

    The absolute event rates (per 100 person-years) were lower in women with scores 5 to 10% (0.42 in rosuvastatin and 0.96 in placebo) compared with women with scores >10% (1.28 and 2.23, respectively)

    PMID 20176986 · one of two readings recorded this

  • Primary endpoint absolute rate

    decreases

    The absolute event rates (per 100 person-years) were lower in women with scores 5 to 10% (0.42 in rosuvastatin and 0.96 in placebo) compared with women with scores >10% (1.28 and 2.23, respectively)

    PMID 20176986 · one of two readings recorded this

  • Primary endpoint (hazard ratio)

    decreases, n = 829

    HRs 0.20, 95% CI 0.06–0.69 and 0.63, 95% CI 0.41–0.96, respectively, P for interaction 0.07

    PMID 20176986 · one of two readings recorded this

  • Primary endpoint (hazard ratio)

    decreases, n = 1646

    Women with Framingham risk scores of 5 to 10% (N=2,525) and >10% (N=1,646) had similar and significant proportional reduction in events (HRs 0.44, 95% CI 0.22–0.89, and 0.57, 95% CI 0.34–0.97)

    PMID 20176986 · one of two readings recorded this

  • Primary endpoint (hazard ratio)

    decreases, n = 2525

    Women with Framingham risk scores of 5 to 10% (N=2,525) and >10% (N=1,646) had similar and significant proportional reduction in events (HRs 0.44, 95% CI 0.22–0.89, and 0.57, 95% CI 0.34–0.97)

    PMID 20176986 · one of two readings recorded this

  • Primary endpoint (hazard ratio)

    no effect

    HRs 0.35, 95% CI 0.19–0.65, and 0.77, 95% CI 0.46–1.30, respectively, P for interaction 0.06

    PMID 20176986 · one of two readings recorded this

  • Primary endpoint (hazard ratio)

    decreases

    HRs 0.20, 95% CI 0.06–0.69 and 0.63, 95% CI 0.41–0.96, respectively, P for interaction 0.07

    PMID 20176986 · one of two readings recorded this

  • Primary endpoint (hazard ratio)

    decreases

    HRs 0.35, 95% CI 0.19–0.65, and 0.77, 95% CI 0.46–1.30, respectively, P for interaction 0.06

    PMID 20176986 · one of two readings recorded this

  • Primary endpoint ratio of relative hazards, women vs men

    no effect

    The HR and 95% CI for the ratio of the relative hazards for treatment in women and men for the primary endpoint were 0.94 (0.60–1.49)

    PMID 20176986 · one of two readings recorded this

  • Primary endpoint treatment-by-sex interaction

    no effect, p = 0.8

    The P-value for a treatment-by-sex interaction using a sex-stratified Cox proportional hazard model was non-significant (P=0.80)

    PMID 20176986 · one of two readings recorded this

  • Revascularization/unstable angina (hazard ratio)

    decreases

    than for men (HR 0.63, 95% CI 0.46–0.85), P for heterogeneity 0.01

    PMID 20176986 · one of two readings recorded this

  • Revascularization/unstable angina (hazard ratio)

    decreases

    Women had significant reduction in revascularization/unstable angina (HR 0.24, 95% CI 0.11–0.51)

    PMID 20176986 · one of two readings recorded this

  • Total mortality, statin trials in women (meta-analysis, relative risk)

    no effect, p = 0.21, n = 13154

    The summary RR for the 3 exclusively primary prevention trials (N=13,154 women, 216 deaths) that reported sex-specific total mortality was 0.78 (95% CI 0.53–1.15), P=0.21

    PMID 20176986 · one of two readings recorded this

  • Triglycerides change

    decreases

    Triglycerides were reduced by 17 mg/dL (14%) in women on rosuvastatin with no change on placebo

    PMID 20176986 · one of two readings recorded this

  • Blood HDL-cholesterol

    increases

    There was no dose-related effect of rosuvastatin on blood HDL-cholesterol, but overall, rosuvastatin increased HDL by 7%

    PMID 25415541 · one of two readings recorded this

  • HDL-cholesterol, rosuvastatin overall effect, trials pooled

    increases, overall HDL increase of 7%

    Not recorded as a finding: Sentence joins a no-dose-response finding to an overall 7% increase in one clause and gives no interval or test, so no single clean direction span; also pools before-and-after trials

    There was no dose-related effect of rosuvastatin on blood HDL-cholesterol, but overall, rosuvastatin increased HDL by 7%.

    PMID 25415541 · one of two readings recorded this

  • LDL-cholesterol and HDL-cholesterol change on rosuvastatin 1 to 80 mg/day, pooled by generic inverse variance across 18 placebo-controlled and 90 before-and-after trials

    decreases, LDL-cholesterol decreases of 46% to 55% at 10 to 40 mg/day

    Not recorded as a finding: the result compares a group with itself, not with a control

    Rosuvastatin 10 to 40 mg/day caused LDL-cholesterol decreases of 46% to 55%, when all the trials were combined using the generic inverse variance method.

    PMID 25415541 · one of two readings recorded this

  • LDL-cholesterol decrease

    decreases, n = 19596

    Rosuvastatin 10 to 40 mg/day caused LDL-cholesterol decreases of 46% to 55%, when all the trials were combined using the generic inverse variance method

    PMID 25415541 · one of two readings recorded this

  • Withdrawals due to adverse effects (WDAEs)

    no effect

    WDAEs were not statistically different between rosuvastatin and placebo in 10 of 18 of these short-term trials (risk ratio 0.84; 95% confidence interval 0.48 to 1.47)

    PMID 25415541 · one of two readings recorded this

  • CI-AKI heterogeneity (I2)

    no effect, p = 0.22

    No significant heterogeneity existed across studies (I2 = 30%, P = 0.22)

    PMID 26222855 · one of two readings recorded this

  • CI-AKI incidence

    decreases, p = 0.001, n = 4045

    Patients receiving rosuvastatin had a 51% lower risk of CI-AKI compared with controls based on a fixed-effect model (OR = 0.49, 95% CI = 0.37–0.66, P < 0.001)

    PMID 26222855 · one of two readings recorded this

  • CI-AKI incidence

    no effect, p = 0.55

    However, when including CKD patients undergoing elective cardiac catheterization, rosuvastatin treatment showed no effect on preventing CI-AKI (I2 = 0%, OR = 0.81, 95% CI = 0.41–1.61, P = 0.55)

    PMID 26222855 · one of two readings recorded this

  • CI-AKI incidence

    decreases, p = 0.04

    Analysis of the subgroup of patients with CKD indicated that rosuvastatin treatment was beneficial for preventing CI-AKI compared to controls (I2 = 8%, OR = 0.57, 95% CI = 0.34–0.96, P = 0.04)

    PMID 26222855 · one of two readings recorded this

  • CI-AKI incidence

    decreases, p = 0.001

    The result indicated that studies with Jadad score ≥3 had significantly reduced CI-AKI (OR = 0.53, 95% CI, 0.38–0.73, P < 0.001)

    PMID 26222855 · one of two readings recorded this

  • incidence of contrast-induced acute kidney injury (CI-AKI), defined as an absolute SCr rise of 0.5 mg/dL or 25% from baseline within 72 hours of contrast; no named KDIGO/AKIN/RIFLE criteria set

    decreases, OR 0.49, 95% CI 0.37-0.66

    Not recorded as a finding: the paper never states the instrument the node requires

    Patients receiving rosuvastatin had a 51% lower risk of CI-AKI compared with controls based on a fixed-effect model (OR = 0.49, 95% CI = 0.37–0.66, P < 0.001).

    PMID 26222855 · one of two readings recorded this

  • incidence of contrast-induced acute kidney injury, defined as SCr rise of at least 0.5 mg/dL or 25% from baseline within 72 hours, rosuvastatin pretreatment versus placebo, pooled OR

    decreases, OR = 0.49, 95% CI = 0.37–0.66

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    Patients receiving rosuvastatin had a 51% lower risk of CI-AKI compared with controls based on a fixed-effect model (OR = 0.49, 95% CI = 0.37–0.66, P < 0.001).

    PMID 26222855 · one of two readings recorded this

  • Major adverse cardiovascular events (MACEs)

    unclear, p = 0.08

    The incidence of MACEs was only reported in 3 trials, but the trend indicated that rosuvastatin treatment reduced MACEs compared to controls (I2 = 0%, OR = 0.62, 95% CI = 0.36–1.07, P = 0.08)

    PMID 26222855 · one of two readings recorded this

  • Publication bias (Egger's test), CI-AKI

    no effect, p = 0.231

    the result of Egger's test demonstrated no obvious publication bias among the included trials for CI-AKI (P = 0.231) or MACE (P = 0.324)

    PMID 26222855 · one of two readings recorded this

  • Publication bias (Egger's test), MACE

    no effect, p = 0.324

    the result of Egger's test demonstrated no obvious publication bias among the included trials for CI-AKI (P = 0.231) or MACE (P = 0.324)

    PMID 26222855 · one of two readings recorded this

  • death during follow-up (event counts)

    no effect, p = 0.09

    Death | 7(0.7 %) | 15(1.6 %) | 0.09

    PMID 26306625 · one of two readings recorded this

  • death during follow-up (event counts)

    no effect, p = 0.06

    Death | 9(0.7 %) | 18(1.5 %) | 0.06

    PMID 26306625 · one of two readings recorded this

  • death during follow-up (event counts)

    no effect, p = 0.05

    Death | 8(0.7 %) | 17(1.5 %) | 0.05

    PMID 26306625 · one of two readings recorded this

  • death during follow-up (event counts)

    no effect, p = 0.3

    Death | 1(0.4 %) | 2(1.2 %) | 0.3

    PMID 26306625 · one of two readings recorded this

  • death during follow-up (event counts)

    no effect, p = 0.42

    Death | 2(0.6 %) | 3(1.0 %) | 0.42

    PMID 26306625 · one of two readings recorded this

  • death during follow-up (event counts)

    no effect, p = 0.09

    Death | 7(0.7 %) | 15(1.6 %) | 0.09

    PMID 26306625 · one of two readings recorded this

  • MACE during follow-up (event counts)

    decreases, p = 0.0001

    MACE | 33(3.5 %) | 72(7.6 %) | <0.0001

    PMID 26306625 · one of two readings recorded this

  • MACE during follow-up (event counts)

    decreases, p = 0.00001

    MACE | 45(3.5 %) | 94(7.6 %) | <0.00001

    PMID 26306625 · one of two readings recorded this

  • MACE during follow-up (event counts)

    decreases, p = 0.00001

    MACE | 41(3.4 %) | 90(8.0 %) | <0.00001

    PMID 26306625 · one of two readings recorded this

  • MACE during follow-up (event counts)

    decreases, p = 0.01

    MACE | 6(2.4 %) | 14(8.4 %) | 0.01

    PMID 26306625 · one of two readings recorded this

  • MACE during follow-up (event counts)

    decreases, p = 0.02

    MACE | 12(3.3 %) | 22(7.7 %) | 0.02

    PMID 26306625 · one of two readings recorded this

  • MACE during follow-up (event counts)

    decreases, p = 0.0001

    MACE | 35(3.7 %) | 76(8.0 %) | <0.0001

    PMID 26306625 · one of two readings recorded this

  • MACE, pooled

    decreases, p = 0.0001

    a 58 % relative reduction in MACE for ACS patients (OR = 0.42, 95 % CI: 0.27-0.65, P < 0.0001; I2 = 0 %)

    PMID 26306625 · one of two readings recorded this

  • MACE, pooled

    decreases, p = 0.00001

    a 60 % relative reduction of MACE in all the enrolled patients (OR = 0.40, 95 % CI: 0.27-0.58, P < 0.00001; I2 = 0 %)

    PMID 26306625 · one of two readings recorded this

  • MACE, pooled

    decreases, p = 0.01

    a 72 % relative reduction in the previous statin therapy group (OR = 0.28, 95 % CI: 0.10-0.73, P = 0.01; I2 = 0 %)

    PMID 26306625 · one of two readings recorded this

  • MACE, pooled

    decreases, p = 0.02

    RSV preloading before PCI lead to a 58 % relative reduction in MACE for stable angina patients (OR = 0.42, 95 % CI: 0.21-0.87, P = 0.02; I2 = 10 %)

    PMID 26306625 · one of two readings recorded this

  • MACE, pooled

    decreases, p = 0.0001

    a 58 % relative reduction in the statin naïve group (OR = 0.42, 95 % CI: 0.28-0.64, P < 0.0001; I2 = 0 %)

    PMID 26306625 · one of two readings recorded this

  • major adverse cardiac events (MACE), pooled

    decreases, p = 0.00001

    The overall outcome for MACE showed that RSV preloading lead to a 58 % relative reduction in MACE (OR = 0.42, 95 % CI: 0.29-0.61, P < 0.00001; Fig. 4)

    PMID 26306625 · one of two readings recorded this

  • major adverse cardiac events (mortality, spontaneous MI, target vessel revascularization) during follow-up; also peri-procedural myocardial injury and post-PCI TIMI flow grade 3; high-dose rosuvastatin preloading before PCI, controls mixed placebo, no statin and lower-dose rosuvastatin

    decreases, OR 0.42, 95% CI 0.29-0.61

    Not recorded as a finding: this platform holds no node for the endpoint

    The overall outcome for MACE showed that RSV preloading lead to a 58 % relative reduction in MACE (OR = 0.42, 95 % CI: 0.29-0.61, P < 0.00001; Fig. 4).

    PMID 26306625 · one of two readings recorded this

  • major adverse cardiac events, peri-procedural myocardial injury and post-PCI TIMI flow grade 3, high-dose rosuvastatin preloading versus control (placebo, no statin, or low-dose rosuvastatin), pooled OR

    decreases, OR = 0.42, 95 % CI: 0.29-0.61

    Not recorded as a finding: the comparison was against another active treatment

    The overall outcome for MACE showed that RSV preloading lead to a 58 % relative reduction in MACE (OR = 0.42, 95 % CI: 0.29-0.61, P < 0.00001; Fig. 4).

    PMID 26306625 · one of two readings recorded this

  • peri-procedural myocardial injury (PMI), pooled

    decreases, p = 0.0001

    The overall outcome for PMI showed that RSV preloading lead to a 60 % relative reduction in PMI (OR = 0.40, 95 % CI: 0.25-0.63, P < 0.0001; Fig. 5)

    PMID 26306625 · one of two readings recorded this

  • PMI, pooled

    decreases, p = 0.0001

    a 57 % reduction in PMI for ACS patients (OR = 0.43, 95 % CI: 0.29-0.65, P < 0.0001; I2 = 0 %)

    PMID 26306625 · one of two readings recorded this

  • PMI, pooled

    decreases, p = 0.00001

    a 67 % relative reduction of PMI in all the enrolled patients (OR = 0.33, 95 % CI: 0.25-0.45, P < 0.00001; I2 = 0 %)

    PMID 26306625 · one of two readings recorded this

  • PMI, pooled

    decreases, p = 0.0001

    a 69 % relative reduction in the previous statin therapy group (OR = 0.31, 95 % CI: 0.17-0.55, P < 0.0001; I2 = 39 %)

    PMID 26306625 · one of two readings recorded this

  • PMI, pooled

    decreases, p = 0.04

    a 63 % reduction in PMI for stable angina patients (OR = 0.37, 95 % CI: 0.14-0.97, P = 0.04; I2 = 81 %)

    PMID 26306625 · one of two readings recorded this

  • PMI, pooled

    decreases, p = 0.00001

    a 66 % relative reduction in the statin naïve group (OR = 0.34, 95 % CI: 0.24-0.49, P < 0.00001; I2 = 0 %)

    PMID 26306625 · one of two readings recorded this

  • post-PCI TIMI flow grade 3

    increases, p = 0.02

    The overall outcome indicated that RSV preloading lead to a 61 % relative increase in post-PCI TIMI flow grade 3 (OR = 1.61, 95 % CI: 1.09-2.38, P = 0.02; Fig. 3)

    PMID 26306625 · one of two readings recorded this

  • publication bias (Egger's regression), MACE funnel plot

    no effect, p = 0.139

    Funnel plots for MACE were generated using a fixed effect model (P = 0.139 > 0.05)

    PMID 26306625 · one of two readings recorded this

  • publication bias (Egger's regression), PMI funnel plot

    no effect, p = 0.273

    for PMI were generated using a random effects model (P = 0.273 > 0.05)

    PMID 26306625 · one of two readings recorded this

  • spontaneous MI during follow-up (event counts)

    decreases, p = 0.02

    Spontaneous MI | 7(0.7 %) | 20(2.1 %) | 0.02

    PMID 26306625 · one of two readings recorded this

  • spontaneous MI during follow-up (event counts)

    decreases, p = 0.01

    Spontaneous MI | 12(0.9 %) | 27(2.2 %) | 0.01

    PMID 26306625 · one of two readings recorded this

  • spontaneous MI during follow-up (event counts)

    decreases, p = 0.005

    Spontaneous MI | 10(0.8 %) | 26(2.3 %) | 0.005

    PMID 26306625 · one of two readings recorded this

  • spontaneous MI during follow-up (event counts)

    no effect, p = 0.13

    Spontaneous MI | 2(0.8 %) | 5(3.0 %) | 0.13

    PMID 26306625 · one of two readings recorded this

  • spontaneous MI during follow-up (event counts)

    no effect, p = 0.34

    Spontaneous MI | 5(1.4 %) | 7(2.4 %) | 0.34

    PMID 26306625 · one of two readings recorded this

  • spontaneous MI during follow-up (event counts)

    decreases, p = 0.02

    Spontaneous MI | 8(0.8 %) | 21(2.2 %) | 0.02

    PMID 26306625 · one of two readings recorded this

  • TVR during follow-up (event counts)

    decreases, p = 0.01

    TVR | 19(2.0 %) | 37(3.9 %) | 0.01

    PMID 26306625 · one of two readings recorded this

  • TVR during follow-up (event counts)

    decreases, p = 0.002

    TVR | 24(1.8 %) | 49(4.0 %) | 0.002

    PMID 26306625 · one of two readings recorded this

  • TVR during follow-up (event counts)

    decreases, p = 0.002

    TVR | 23(1.9 %) | 47(4.2 %) | 0.002

    PMID 26306625 · one of two readings recorded this

  • TVR during follow-up (event counts)

    no effect, p = 0.09

    TVR | 3(1.2 %) | 7(4.2 %) | 0.09

    PMID 26306625 · one of two readings recorded this

  • TVR during follow-up (event counts)

    no effect, p = 0.05

    TVR | 5(1.4 %) | 12(4.2 %) | 0.05

    PMID 26306625 · one of two readings recorded this

  • TVR during follow-up (event counts)

    decreases, p = 0.008

    TVR | 20(2.1 %) | 40(4.2 %) | 0.008

    PMID 26306625 · one of two readings recorded this

  • cTnT after PCI

    decreases

    the level of cTnT at 24 h after PCI (SMD = -1.93, 95%CI -2.28 ~ -1.59, P = 0.000)

    PMID 28231287 · one of two readings recorded this

  • HDL-C after PCI

    increases

    the loading dose of rosuvastatin can significantly increase the level of HDL-C at 48 h after PCI (SMD = 0.61, 95%CI 0.34 ~ 0.88, P = 0.000)

    PMID 28231287 · one of two readings recorded this

  • hs-CRP after PCI at 24 h, 48 h and 4 weeks; also LDL-C, HDL-C, TG, TC, cTnT; rosuvastatin 20 mg/day loading versus 10 mg/day conventional dose

    decreases, SMD -0.65 at 24 h, 95% CI -0.84 to -0.47

    Not recorded as a finding: the comparison was against another active treatment

    Meta-analysis results showed that compared with the that of the conventional dose group, the loading dose of rosuvastatin can significantly reduce the hs-CRP level after PCI, including at 24 hours (SMD = -0.65, 95%CI -0.84 ~ -0.47, P = 0.000), 48 hours (SMD = -0.40, 95%CI -0.68 ~ -0.11,P = 0.006) and 4 weeks (SMD = -1.64, 95%CI -2.01 ~ -1.26, P = 0.000).

    PMID 28231287 · one of two readings recorded this

  • hs-CRP after PCI

    decreases

    including at 24 hours (SMD = -0.65, 95%CI -0.84 ~ -0.47, P = 0.000)

    PMID 28231287 · one of two readings recorded this

  • hs-CRP after PCI

    decreases

    4 weeks (SMD = -1.64, 95%CI -2.01 ~ -1.26, P = 0.000)

    PMID 28231287 · one of two readings recorded this

  • hs-CRP after PCI

    decreases, p = 0.006

    48 hours (SMD = -0.40, 95%CI -0.68 ~ -0.11,P = 0.006)

    PMID 28231287 · one of two readings recorded this

  • hs-CRP, LDL-C, HDL-C, triglycerides, total cholesterol and cTnT after PCI, rosuvastatin 20 mg/day loading dose versus 10 mg/day conventional dose, pooled SMD

    decreases, hs-CRP at 24 hours SMD = -0.65, 95% CI -0.84 ~ -0.47

    Not recorded as a finding: the comparison was against another active treatment

    Meta-analysis results showed that compared with the that of the conventional dose group, the loading dose of rosuvastatin can significantly reduce the hs-CRP level after PCI, including at 24 hours (SMD = -0.65, 95%CI -0.84 ~ -0.47, P = 0.000), 48 hours (SMD = -0.40, 95%CI -0.68 ~ -0.11,P = 0.006) and 4 weeks (SMD = -1.64, 95%CI -2.01 ~ -1.26, P = 0.000).

    PMID 28231287 · one of two readings recorded this

  • LDL-C after PCI

    decreases

    the level of LDL-C at 30 d after PCI (SMD = -0.89, 95%CI -1.10 ~ -0.69, P = 0.000)

    PMID 28231287 · one of two readings recorded this

  • LDL-C after PCI

    no effect, p = 0.513

    but cannot reduce the level of LDL-C at 48 h after PCI (P = 0.513)

    PMID 28231287 · one of two readings recorded this

  • publication bias (Egger's test), hs-CRP change after PCI

    unclear, p = 0.014

    Egger’s test demonstrated obvious publication bias under the change of hs-CRP after PCI (P = 0.014)

    PMID 28231287 · one of two readings recorded this

  • publication bias (Egger's test), LDL-C, HDL-C and cTnT change after PCI

    unclear, p = 0.003

    and the change of LDL-C,HDL-C and cTnT after PCI (P = 0.003)

    PMID 28231287 · one of two readings recorded this

  • publication bias (Egger's test), TG and TC change after PCI

    no effect, p = 0.841

    Egger’s test did not exhibit obvious publication bias under the change of TG and TC after PCI (P = 0.841)

    PMID 28231287 · one of two readings recorded this

  • total cholesterol (TC) after PCI

    no effect

    but cannot reduce the level of TG at 48 h after PCI and the level of TC at 24 h after PCI

    PMID 28231287 · one of two readings recorded this

  • total cholesterol (TC) after PCI

    decreases

    the level of TC at 30 d after PCI (SMD = -0.77, 95%CI -0.98 ~ -0.56, P = 0.000)

    PMID 28231287 · one of two readings recorded this

  • total cholesterol (TC) after PCI

    decreases, p = 0.043

    the level of TC at 48 h after PCI (SMD = -0.35, 95%CI -0.68 ~ -0.01, P = 0.043)

    PMID 28231287 · one of two readings recorded this

  • triglycerides (TG) after PCI

    decreases

    the level of TG at 30 d after PCI (SMD = -0.94, 95%CI -1.17 ~ -0.71, P = 0.000)

    PMID 28231287 · one of two readings recorded this

  • triglycerides (TG) after PCI

    no effect

    but cannot reduce the level of TG at 48 h after PCI and the level of TC at 24 h after PCI

    PMID 28231287 · one of two readings recorded this

  • cystatin C (CysC) after operation

    decreases, p = 0.03

    CysC 24 hours: SMD = −0.54, 95% CI −1.02 to −0.05, P =.03

    PMID 28682890 · one of two readings recorded this

  • cystatin C (CysC) after operation

    decreases, p = 0.004

    CysC 72 hours: SMD = −0.66, 95% CI −1.11 to −0.21, P =.004

    PMID 28682890 · one of two readings recorded this

  • hs-CRP after operation

    decreases, p = 0.01

    hs-CRP 24 hours: SMD = −0.54, 95% CI −0.96 to −0.12, P =.01

    PMID 28682890 · one of two readings recorded this

  • hs-CRP after operation

    decreases, p = 0.0001

    hs-CRP 72 hours: SMD = −1.01, 95% CI −1.45 to −0.56, P <.0001

    PMID 28682890 · one of two readings recorded this

  • incidence of CIN

    decreases, p = 0.0001

    the same effect was seen in other comparisons between moderate or high-dose rosuvastatin treatment group with placebo group (RR = 0.49, 95% CI 0.35–0.69, P <.0001; I2 = 17%)

    PMID 28682890 · one of two readings recorded this

  • incidence of CIN

    decreases, p = 0.0001

    studies that received moderate or high-dose rosuvastatin treatment had significantly reduced incidence of CIN than those that received low-dose rosuvastatin treatment (RR = 0.40, 95% CI 0.27–0.59, P <.0001; I2 = 0%)

    PMID 28682890 · one of two readings recorded this

  • incidence of CIN

    decreases, p = 0.006

    moderate (20 mg) or high dose (≥40 mg) rosuvastatin significantly reduced the incidence of CIN compared with the control (RR = 0.39, 95% CI 0.29–0.54, P <.0001, RR = 0.56, 95% CI 0.37–0.85, P =.006, respectively)

    PMID 28682890 · one of two readings recorded this

  • incidence of CIN

    decreases, p = 0.0001

    moderate (20 mg) or high dose (≥40 mg) rosuvastatin significantly reduced the incidence of CIN compared with the control (RR = 0.39, 95% CI 0.29–0.54, P <.0001, RR = 0.56, 95% CI 0.37–0.85, P =.006, respectively)

    PMID 28682890 · one of two readings recorded this

  • incidence of CIN

    decreases, p = 0.0009

    in ACS patients undergoing PCI (RR = 0.52, 95% CI 0.35–0.76, P =.0009; I2 = 0%)

    PMID 28682890 · one of two readings recorded this

  • incidence of CIN

    decreases, p = 0.03

    indicated that moderate or high-dose rosuvastatin treatment also significantly reduced risk of CIN than control group (RR = 0.53, 95% CI 0.30–0.93, P =.03; I2 = 11%)

    PMID 28682890 · one of two readings recorded this

  • incidence of CIN

    decreases, p = 0.01

    seen in patients with DM (RR = 0.51, 95% CI 0.31–0.86, P =.01; I2 = 0%)

    PMID 28682890 · one of two readings recorded this

  • incidence of CIN

    decreases, p = 0.0001

    in studies that received contrast volume ≥110 mL (RR = 0.43, 95% CI 0.32–0.58, P <.0001; I2 = 0%)

    PMID 28682890 · one of two readings recorded this

  • incidence of contrast-induced nephropathy (CIN)

    decreases, p = 0.0001, n = 2673

    Patients who received moderate or high-dose rosuvastatin pretreatment had a 55% lower risk of CIN compared with low-dose rosuvastatin pretreatment or placebo group based on a fixed effect model (RR = 0.45, 95% CI 0.35–0.58, P <.0001)

    PMID 28682890 · one of two readings recorded this

  • incidence of contrast-induced nephropathy (SCr rise of 25% or 44.2 umol/L within 2 to 5 days), moderate or high-dose rosuvastatin versus low-dose rosuvastatin or placebo, pooled RR; also SCr, cystatin C, hs-CRP, urine microalbumin

    decreases, RR = 0.45, 95% CI 0.35-0.58

    Not recorded as a finding: the comparison was against another active treatment

    Patients who received moderate or high-dose rosuvastatin pretreatment had a 55% lower risk of CIN compared with low-dose rosuvastatin pretreatment or placebo group based on a fixed effect model (RR = 0.45, 95% CI 0.35–0.58, P <.0001).

    PMID 28682890 · one of two readings recorded this

  • incidence of contrast-induced nephropathy, SCr rise of 25% or 44.2 umol/L within 2 to 5 days; moderate or high-dose rosuvastatin versus low-dose rosuvastatin or placebo pooled

    decreases, RR 0.45, 95% CI 0.35-0.58

    Not recorded as a finding: the comparison was against another active treatment

    Patients who received moderate or high-dose rosuvastatin pretreatment had a 55% lower risk of CIN compared with low-dose rosuvastatin pretreatment or placebo group based on a fixed effect model (RR = 0.45, 95% CI 0.35–0.58, P <.0001).

    PMID 28682890 · one of two readings recorded this

  • serum creatinine (SCr) after operation

    no effect, p = 0.06

    SCr 24 hours: SMD = −0.30, 95% CI −0.62 to 0.01, P =.06

    PMID 28682890 · one of two readings recorded this

  • serum creatinine (SCr) after operation

    decreases, p = 0.02

    SCr 72 hours: SMD = −0.27, 95% CI −0.49 to −0.05, P =.02

    PMID 28682890 · one of two readings recorded this

  • urine microalbumin (mALB) after operation

    decreases, p = 0.01

    mALB 24 hours: SMD = −0.73, 95% CI −1.32 to −0.15, P =.01

    PMID 28682890 · one of two readings recorded this

  • urine microalbumin (mALB) after operation

    no effect, p = 0.09

    mALB 72 hours: SMD = −0.52, 95% CI −1.12 to 0.08, P =.09

    PMID 28682890 · one of two readings recorded this

  • incidence of CI-AKI

    decreases, p = 0.04

    Rosuvastatin reduced also the risk of CI-AKI in patients with CKD (OR: 0.45, 95% CI: 0.21–0.95, P=0.04) and DM (OR: 0.56, 95% CI: 0.38–0.83, P=0.004), as compared with that in the placebo group

    PMID 30464400 · one of two readings recorded this

  • incidence of CI-AKI

    decreases, p = 0.004

    Rosuvastatin reduced also the risk of CI-AKI in patients with CKD (OR: 0.45, 95% CI: 0.21–0.95, P=0.04) and DM (OR: 0.56, 95% CI: 0.38–0.83, P=0.004), as compared with that in the placebo group

    PMID 30464400 · one of two readings recorded this

  • incidence of contrast-induced acute kidney injury (CI-AKI/CIN) after rosuvastatin pretreatment versus placebo, pooled odds ratio; no named criteria set (KDIGO, AKIN, RIFLE) stated in Methods or Results

    decreases, OR 0.53, 95% CI 0.40-0.71

    Not recorded as a finding: the paper never states the instrument the node requires

    The data pooled from all five articles included in our research showed that the risk of CI-AKI (OR: 0.53, 95% CI: 0.40–0.71, P<0.0001) in the atorvastatin treatment group was lower than that in the control group.

    PMID 30464400 · one of two readings recorded this

  • incidence of contrast-induced acute kidney injury (CI-AKI/CIN), pooled OR across five RCTs of rosuvastatin pretreatment before coronary angiography; no KDIGO/AKIN criteria set stated

    decreases, CKD subgroup OR 0.45, 95% CI 0.21-0.95, p = 0.04

    Not recorded as a finding: every result is a subgroup, with no whole-population estimate

    Rosuvastatin reduced also the risk of CI-AKI in patients with CKD (OR: 0.45, 95% CI: 0.21–0.95, P=0.04) and DM (OR: 0.56, 95% CI: 0.38–0.83, P=0.004), as compared with that in the placebo group.

    PMID 30464400 · one of two readings recorded this

  • incidence of contrast-induced acute kidney injury (CI-AKI), pooled

    decreases, p = 0.0001

    The data pooled from all five articles included in our research showed that the risk of CI-AKI (OR: 0.53, 95% CI: 0.40–0.71, P<0.0001) in the atorvastatin treatment group was lower than that in the control group

    PMID 30464400 · one of two readings recorded this

  • venous thromboembolism (deep vein thrombosis or pulmonary embolism) incidence during follow-up, pooled individual participant data from two RCTs

    decreases, hazard ratio 0.53, 95% CI 0.37-0.75, n = 30507

    Not recorded as a finding: this platform holds no node for the endpoint

    In the pooled cohort, rosuvastatin was associated with a large proportional reduction in the risk of VTE (hazard ratio 0.53, 95% CI 0.37-0.75).

    PMID 33705531 · one of two readings recorded this

  • venous thromboembolism (deep vein thrombosis or pulmonary embolism) incidence

    decreases, hazard ratio 0.53, 95% CI 0.37-0.75

    Not recorded as a finding: this platform holds no node for the endpoint

    In the pooled cohort, rosuvastatin was associated with a large proportional reduction in the risk of VTE (hazard ratio 0.53, 95% CI 0.37-0.75).

    PMID 33705531 · one of two readings recorded this

  • venous thromboembolism (deep vein thrombosis or pulmonary embolism)

    decreases, hazard ratio 0.53, 95% CI 0.37-0.75, n = 30507

    In the pooled cohort, rosuvastatin was associated with a large proportional reduction in the risk of VTE (hazard ratio 0.53, 95% CI 0.37-0.75).

    PMID 33705531 · both readings recorded this

  • venous thromboembolism (deep vein thrombosis or pulmonary embolism)

    decreases, n = 30507

    In the pooled cohort, rosuvastatin was associated with a large proportional reduction in the risk of VTE (hazard ratio 0.53, 95% CI 0.37-0.75)

    PMID 33705531 · one of two readings recorded this

  • venous thromboembolism, interaction of rosuvastatin effect across demographic, CVD risk factor and cancer-history subgroups

    no effect, p = 0.05

    No significant interactions were observed between treatment with rosuvastatin and the risk of VTE across subpopulations stratified by demographic, CVD risk factors, or a history of cancer (P-values for interactions >0.05 for all subgroups)

    PMID 33705531 · one of two readings recorded this

  • venous thromboembolism, subgroup interaction testing

    no effect

    No significant interactions were observed between treatment with rosuvastatin and the risk of VTE across subpopulations stratified by demographic, CVD risk factors, or a history of cancer (P-values for interactions >0.05 for all subgroups).

    PMID 33705531 · one of two readings recorded this

  • systolic blood pressure (setting unspecified)

    MD = −2.27 mmHg; 95% CI = −4.79 to 0.25; Pfixed-effects model = 0.08, p = 0.08

    Not recorded as a finding: The sentence negates only one tail ('not associated with a significant reduction'), and no sentence in the paper states a two-sided absence of difference for SBP, so no direction is recordable per the one-sided-negation rule.

    However, rosuvastatin therapy was not associated with a significant reduction in SBP (MD = −2.27 mmHg; 95% CI = −4.79 to 0.25; Pfixed-effects model = 0.08; I 2 = 0%, Pheterogeneity = 0.82).

    PMID 34818350 · one of two readings recorded this

  • systolic blood pressure (SBP) change from baseline

    MD = -2.27 mmHg; 95% CI = -4.79 to 0.25, p = 0.08

    However, rosuvastatin therapy was not associated with a significant reduction in SBP (MD = −2.27 mmHg; 95% CI = −4.79 to 0.25; Pfixed-effects model = 0.08; I 2 = 0%, Pheterogeneity = 0.82).

    PMID 34818350 · one of two readings recorded this

  • systolic blood pressure (SBP), pooled mean difference across RCTs

    MD = −2.27 mmHg; 95% CI = −4.79 to 0.25, p = 0.08

    Not recorded as a finding: the sentence states only a one-sided 'not associated with a significant reduction' (ADR rule 1a); no two-sided no-difference statement exists in Results to support no_effect, so direction is not recordable

    However, rosuvastatin therapy was not associated with a significant reduction in SBP (MD = −2.27 mmHg; 95% CI = −4.79 to 0.25; Pfixed-effects model = 0.08; I 2 = 0%, Pheterogeneity = 0.82).

    PMID 34818350 · one of two readings recorded this

  • systolic blood pressure (SBP)

    MD = −2.27 mmHg; 95% CI = −4.79 to 0.25; Pfixed-effects model = 0.08, p = 0.08

    However, rosuvastatin therapy was not associated with a significant reduction in SBP (MD = −2.27 mmHg; 95% CI = −4.79 to 0.25; Pfixed-effects model = 0.08; I 2 = 0%, Pheterogeneity = 0.82).

    PMID 34818350 · one of two readings recorded this

  • composite adverse events

    no effect, odds ratio 0.50; 95% CI 0.15 to 1.72, p = 0.27

    Based on three studies (I2=0%; p for heterogeneity=0.84), the risk of composite AEs (common effect model; odds ratio 0.50; 95% CI 0.15 to 1.72; p=0.27) of the combination was not different compared to the monotherapy group.

    PMID 38154476 · one of two readings recorded this

  • composite adverse events

    no effect, odds ratio 0.50; 95% CI 0.15 to 1.72; p=0.27, p = 0.27

    Based on three studies (I2=0%; p for heterogeneity=0.84), the risk of composite AEs (common effect model; odds ratio 0.50; 95% CI 0.15 to 1.72; p=0.27) of the combination was not different compared to the monotherapy group.

    PMID 38154476 · one of two readings recorded this

  • percentage HDL-C elevation

    no effect, p = 0.86

    Likewise, the percentages HDL-C elevation (I2=0%; p for heterogeneity=0.85) were not different between the two groups (common effect model; 95% CI -0.20 to 0.17; p=0.86).

    PMID 38154476 · one of two readings recorded this

  • percentage HDL-C elevation

    no effect, 95% CI -0.20 to 0.17; p=0.86, p = 0.86

    Likewise, the percentages HDL-C elevation (I2=0%; p for heterogeneity=0.85) were not different between the two groups (common effect model; 95% CI -0.20 to 0.17; p=0.86).

    PMID 38154476 · one of two readings recorded this

  • percentage LDL-C reduction (primary outcome)

    no effect, SMD 0.08; 95% CI -0.09 to 0.26; p=0.35, p = 0.35

    Based on five studies (I2=0%; p for heterogeneity=0.70), the percentage LDL-C reduction did not differ between 5 mg rosuvastatin/10 mg ezetimibe and 20 mg rosuvastatin [common effect model; standardized mean difference (SMD) 0.08; 95% CI -0.09 to 0.26; p=0.35].

    PMID 38154476 · one of two readings recorded this

  • percentage LDL-C reduction

    no effect, SMD 0.08; 95% CI -0.09 to 0.26, p = 0.35

    Based on five studies (I2=0%; p for heterogeneity=0.70), the percentage LDL-C reduction did not differ between 5 mg rosuvastatin/10 mg ezetimibe and 20 mg rosuvastatin [common effect model; standardized mean difference (SMD) 0.08; 95% CI -0.09 to 0.26; p=0.35].

    PMID 38154476 · one of two readings recorded this

  • percentage reduction in LDL-C (primary outcome), plus TC, TG, HDL-C elevation, and composite adverse events, comparing 5 mg rosuvastatin/10 mg ezetimibe with 20 mg rosuvastatin monotherapy

    no effect, SMD 0.08; 95% CI -0.09 to 0.26; p=0.35, p = 0.35

    Not recorded as a finding: the comparison was against another active treatment

    Based on five studies (I2=0%; p for heterogeneity=0.70), the percentage LDL-C reduction did not differ between 5 mg rosuvastatin/10 mg ezetimibe and 20 mg rosuvastatin [common effect model; standardized mean difference (SMD) 0.08; 95% CI -0.09 to 0.26; p=0.35].

    PMID 38154476 · one of two readings recorded this

  • percentage reduction in LDL-C with rosuvastatin, compared between 5 mg rosuvastatin/10 mg ezetimibe and 20 mg rosuvastatin monotherapy

    no effect, SMD 0.08; 95% CI -0.09 to 0.26, p = 0.35

    Not recorded as a finding: the comparison was against another active treatment

    Based on five studies (I2=0%; p for heterogeneity=0.70), the percentage LDL-C reduction did not differ between 5 mg rosuvastatin/10 mg ezetimibe and 20 mg rosuvastatin [common effect model; standardized mean difference (SMD) 0.08; 95% CI -0.09 to 0.26; p=0.35].

    PMID 38154476 · one of two readings recorded this

  • percentage total cholesterol (TC) reduction

    increases, SMD 0.22; 95% CI 0.04 to 0.41, p = 0.02

    Based on four studies (I2=47%; p for heterogeneity=0.13), the percentage TC reduction was greater in the 5 mg rosuvastatin/10 mg ezetimibe group (common effect model; SMD 0.22; 95% CI 0.04 to 0.41; p=0.02).

    PMID 38154476 · one of two readings recorded this

  • percentage total cholesterol (TC) reduction

    decreases, SMD 0.22; 95% CI 0.04 to 0.41; p=0.02, p = 0.02

    Based on four studies (I2=47%; p for heterogeneity=0.13), the percentage TC reduction was greater in the 5 mg rosuvastatin/10 mg ezetimibe group (common effect model; SMD 0.22; 95% CI 0.04 to 0.41; p=0.02).

    PMID 38154476 · one of two readings recorded this

  • percentage triglyceride (TG) reduction

    no effect, SMD -0.27; 95% CI -0.84 to 0.30, p = 0.36

    The percentage TG reduction of the two regimens (I2=89%; p for heterogeneity<0.01) did not differ (random effect model; SMD -0.27; 95% CI -0.84 to 0.30; p=0.36).

    PMID 38154476 · one of two readings recorded this

  • percentage triglyceride (TG) reduction

    no effect, SMD -0.27; 95% CI -0.84 to 0.30; p=0.36, p = 0.36

    The percentage TG reduction of the two regimens (I2=89%; p for heterogeneity<0.01) did not differ (random effect model; SMD -0.27; 95% CI -0.84 to 0.30; p=0.36).

    PMID 38154476 · one of two readings recorded this

  • LDL-C change

    decreases, MD -8.06, 95% CI [-9.48, -6.64]

    Meta-analysis showed that the combination group improved LDL-C better than the monotherapy group, and the difference was statistically significant (MD -8.06, 95% CI [-9.48, -6.64] p < 0.05).

    PMID 39536001 · one of two readings recorded this

  • LDL-C

    decreases, MD -8.06, 95% CI [-9.48, -6.64] p < 0.05

    Meta-analysis showed that the combination group improved LDL-C better than the monotherapy group, and the difference was statistically significant (MD -8.06, 95% CI [-9.48, -6.64] p < 0.05).

    PMID 39536001 · one of two readings recorded this

  • total cholesterol (TC)

    decreases, MD = −7.15, 95% CI (−8.78, −5.53), P < 0.05

    The findings demonstrated a statistically significant difference in TC improvement between patients with the CA + AA genotype and those with the CC genotype [MD = −7.15, 95% CI (−8.78, −5.53), P < 0.05].

    PMID 40082758 · one of two readings recorded this

  • HDL-C percentage change, CA+AA vs CC genotype

    no effect, MD = -2.22, 95% CI (-19.87, 15.43), p = 0.81

    The findings demonstrated that there was no statistically significant difference in the level of HDL-C improvement between patients with the CA + AA genotype and those with the CC genotype [MD = −2.22, 95% CI (−19.87, 15.43), P = 0.81].

    PMID 40082758 · one of two readings recorded this

  • HDL-C

    no effect, MD = −2.22, 95% CI (−19.87, 15.43), P = 0.81, p = 0.81

    The findings demonstrated that there was no statistically significant difference in the level of HDL-C improvement between patients with the CA + AA genotype and those with the CC genotype [MD = −2.22, 95% CI (−19.87, 15.43), P = 0.81].

    PMID 40082758 · one of two readings recorded this

  • total cholesterol (TC) percentage change, CA+AA vs CC genotype

    decreases, MD = -7.15, 95% CI (-8.78, -5.53)

    The findings demonstrated a statistically significant difference in TC improvement between patients with the CA + AA genotype and those with the CC genotype [MD = −7.15, 95% CI (−8.78, −5.53), P < 0.05].

    PMID 40082758 · one of two readings recorded this

  • triglycerides (TG) percentage change, CA+AA vs CC genotype

    decreases, MD = -7.34, 95% CI (-10.88, -3.80)

    The findings demonstrated that patients with the CA + AA genotype had a statistically significant improvement in TG compared to those with the CC genotype [MD = −7.34, 95% CI (−10.88, −3.80), P < 0.05].

    PMID 40082758 · one of two readings recorded this

  • triglycerides (TG)

    decreases, MD = −7.34, 95% CI (−10.88, −3.80), P < 0.05

    The findings demonstrated that patients with the CA + AA genotype had a statistically significant improvement in TG compared to those with the CC genotype [MD = −7.34, 95% CI (−10.88, −3.80), P < 0.05].

    PMID 40082758 · one of two readings recorded this

  • TNF-α

    decreases

    Additionally, it significantly reduced levels of hs-CRP, TNF-α, IL-6, IL-8, NE, and Gal-3.

    PMID 40529224 · both readings recorded this

  • IL-6

    decreases, n = 911

    Additionally, it significantly reduced levels of hs-CRP, TNF-α, IL-6, IL-8, NE, and Gal-3.

    PMID 40529224 · both readings recorded this

  • IL-8

    decreases

    Additionally, it significantly reduced levels of hs-CRP, TNF-α, IL-6, IL-8, NE, and Gal-3.

    PMID 40529224 · both readings recorded this

  • FEV1/FVC ratio, difference between pulmonary hypertension and non-comorbid subgroups

    no effect, p = 0.44

    However, the difference between the two subgroups was not statistically significant (P = 0.44, I² = 0%)

    PMID 40529224 · one of two readings recorded this

  • FEV1/FVC ratio, pooled after sensitivity exclusion of Yao W 2020

    increases

    Re-analysis of the remaining seven trials yielded a heterogeneity test result of (P = 0.40, I² = 4%), with an MD of 4.99 and a 95% confidence interval of [4.05, 5.92]

    PMID 40529224 · one of two readings recorded this

  • FEV1/FVC ratio, pooled

    increases, p = 0.0004, n = 737

    The meta-analysis results indicated that the combined effect size MD was 6.36, with a 95% confidence interval of [2.86, 9.86], and the difference was statistically significant (Z = 3.56, P = 0.0004)

    PMID 40529224 · one of two readings recorded this

  • FEV1/FVC ratio

    increases, n = 911

    Rosuvastatin was found to improve forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC ratio, and peak expiratory flow (PEF).

    PMID 40529224 · both readings recorded this

  • FEV1, pooled after sensitivity exclusion of Yao W 2020 and Yu H 2017

    increases

    Re-analysis of the remaining four trials yielded a heterogeneity test result of (P = 0.27, I² = 24%), with an MD of 0.35 and a 95% confidence interval of [0.31, 0.40]

    PMID 40529224 · one of two readings recorded this

  • FEV1, pooled

    increases, p = 0.0006, n = 616

    The meta-analysis results revealed that the combined effect size MD was 0.63, with a 95% confidence interval of [0.27, 0.99], and the difference was statistically significant (Z = 3.42, P = 0.0006)

    PMID 40529224 · one of two readings recorded this

  • FEV1, single study Liu YQ 2023 post-treatment

    increases, p = 0.003

    However, post-treatment, the improvement in the experimental group was significantly superior to that in the control group, with a significant difference observed between the two groups (t = 3.252, P = 0.003)

    PMID 40529224 · one of two readings recorded this

  • forced expiratory volume in 1 second (FEV1)

    increases

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    Rosuvastatin was found to improve forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC ratio, and peak expiratory flow (PEF).

    PMID 40529224 · one of two readings recorded this

  • forced expiratory volume in 1 second (FEV1)

    increases

    Rosuvastatin was found to improve forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC ratio, and peak expiratory flow (PEF).

    PMID 40529224 · one of two readings recorded this

  • forced vital capacity (FVC), pooled

    increases, p = 0.00001, n = 378

    Meta-analysis results demonstrated that the combined effect size MD was 0.60, with a 95% confidence interval of [0.48, 0.73], and the difference was statistically significant (Z = 9.18, P < 0.00001)

    PMID 40529224 · one of two readings recorded this

  • forced vital capacity (FVC), single study Liu YQ 2023 post-treatment

    increases, p = 0.033

    However, post-treatment, the improvement in the experimental group was significantly superior to that in the control group, with a significant difference observed between the two groups (t = 2.187, P = 0.033)

    PMID 40529224 · one of two readings recorded this

  • forced vital capacity (FVC)

    increases

    Rosuvastatin was found to improve forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC ratio, and peak expiratory flow (PEF).

    PMID 40529224 · both readings recorded this

  • galectin-3 (Gal-3), pooled

    decreases, p = 0.00001, n = 219

    Similarly, for Gal-3, the combined effect size was MD = −6.01, with a 95% confidence interval of [−6.75, −5.28], also demonstrating statistical significance (Z = 16.01, P < 0.00001)

    PMID 40529224 · one of two readings recorded this

  • galectin-3 (Gal-3)

    decreases

    Additionally, it significantly reduced levels of hs-CRP, TNF-α, IL-6, IL-8, NE, and Gal-3.

    PMID 40529224 · both readings recorded this

  • hs-CRP, change from pre- to post-treatment, single study Chen Y 2013

    decreases, p = 0.05

    The findings of Chen Y 2013 demonstrated a statistically significant difference in the change from pre-treatment to post-treatment between the experimental and control groups, with a mean difference of 19.49 ± 7.10 (P < 0.05)

    PMID 40529224 · one of two readings recorded this

  • hs-CRP, pooled MD across five RCTs of adjunctive rosuvastatin in AECOPD

    decreases, MD -4.54, 95% CI [-5.02, -4.06]

    Not recorded as a finding: the supporting sentence never names the compound

    The meta-analysis revealed that the combined effect size MD was −4.54, with a 95% confidence interval of [−5.02, −4.06], demonstrating statistical significance (Z = 18.64, P < 0.00001), as illustrated in Figure 8.

    PMID 40529224 · one of two readings recorded this

  • hs-CRP, pooled

    decreases, p = 0.00001, n = 482

    The meta-analysis revealed that the combined effect size MD was −4.54, with a 95% confidence interval of [−5.02, −4.06], demonstrating statistical significance (Z = 18.64, P < 0.00001)

    PMID 40529224 · one of two readings recorded this

  • hs-CRP

    decreases, n = 911

    Additionally, it significantly reduced levels of hs-CRP, TNF-α, IL-6, IL-8, NE, and Gal-3.

    PMID 40529224 · both readings recorded this

  • IL-6, pooled

    decreases, p = 0.00001, n = 140

    The meta-analysis indicated that the combined effect size MD was −13.58, with a 95% confidence interval of [−17.52, −9.64], demonstrating statistical significance (Z = 6.76, P < 0.00001)

    PMID 40529224 · one of two readings recorded this

  • IL-8, pooled

    decreases, p = 0.01, n = 134

    The meta-analysis revealed that the combined effect size MD was −38.87, with a 95% confidence interval of [−68.27, −9.48], indicating statistical significance (Z = 2.59, P = 0.010)

    PMID 40529224 · one of two readings recorded this

  • incidence of adverse reactions, single study

    decreases, p = 0.05

    Liu demonstrated that the incidence of adverse reactions in the observation group was significantly lower than in the control group (χ² = 4.0556, P < 0.05)

    PMID 40529224 · one of two readings recorded this

  • neutrophil elastase (NE), pooled

    decreases, p = 0.00001, n = 219

    The meta-analysis results indicated that the combined effect size for NE was MD = −3.26, with a 95% confidence interval of [−3.93, −2.59], showing statistical significance (Z = 9.53, P < 0.00001)

    PMID 40529224 · one of two readings recorded this

  • neutrophil elastase (NE)

    decreases, n = 911

    Additionally, it significantly reduced levels of hs-CRP, TNF-α, IL-6, IL-8, NE, and Gal-3.

    PMID 40529224 · both readings recorded this

  • peak expiratory flow (PEF), pooled

    increases, p = 0.00001, n = 388

    The meta-analysis results showed that the combined effect size MD was 0.67, with a 95% confidence interval of [0.61, 0.73], and the difference was statistically significant (Z = 21.64, P < 0.00001)

    PMID 40529224 · one of two readings recorded this

  • peak expiratory flow (PEF), single study Liu YQ 2023 post-treatment

    increases, p = 0.029

    However, post-treatment, the improvement in the experimental group was significantly superior to that in the control group, with a notable difference between the two groups (t = 2.240, P = 0.029)

    PMID 40529224 · one of two readings recorded this

  • peak expiratory flow (PEF)

    increases

    Rosuvastatin was found to improve forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC ratio, and peak expiratory flow (PEF).

    PMID 40529224 · both readings recorded this

  • publication bias (Egger's test), FEV1/FVC outcome

    unclear, p = 0.004

    Egger’s test results (z = 2.88, P = 0.0040) indicated the presence of publication bias

    PMID 40529224 · one of two readings recorded this

  • TNF-α, single studies Yao W 2020 and Huan YF 2013 (not pooled)

    decreases, p = 0.05

    The findings from Yao W 2020 and Huan YF 2013 both demonstrated that the experimental group significantly reduced TNF-α values compared to the control group (P < 0.05)

    PMID 40529224 · one of two readings recorded this

  • Baseline-ECG heart rate

    no effect, p = 0.091, n = 466

    Heart rate (bpm) | 71.83 ± 12.20 | 73.77 ± 12.51 | 0.091

    PMID 40890448 · one of two readings recorded this

  • Baseline QT interval

    no effect, p = 0.874, n = 466

    QT interval (ms) | 391.89 ± 38.51 | 392.43 ± 34.83 | 0.874

    PMID 40890448 · one of two readings recorded this

  • Baseline QT prolongation, age (per 10 years)

    increases, p = 0.007, n = 466

    Age | 1.68 (1.30–2.18) | < 0.001 | 1.45 (1.11–1.91) | 0.007

    PMID 40890448 · one of two readings recorded this

  • Baseline QT prolongation, age (per 10 years)

    increases, p = 0.001, n = 466

    Age | 1.68 (1.30–2.18) | < 0.001 | 1.45 (1.11–1.91) | 0.007

    PMID 40890448 · one of two readings recorded this

  • Baseline QT prolongation, atrial fibrillation

    increases, p = 0.014, n = 466

    Atrial fibrillation | 4.92 (2.24–10.80) | < 0.001 | 2.89 (1.24–6.74) | 0.014

    PMID 40890448 · one of two readings recorded this

  • Baseline QT prolongation, atrial fibrillation

    increases, p = 0.001, n = 466

    Atrial fibrillation | 4.92 (2.24–10.80) | < 0.001 | 2.89 (1.24–6.74) | 0.014

    PMID 40890448 · one of two readings recorded this

  • Baseline QT prolongation, creatinine

    increases, p = 0.003, n = 466

    Creatinine | 1.11 (1.01–1.22) | 0.003 | -- | --

    PMID 40890448 · one of two readings recorded this

  • Baseline QT prolongation, heart failure

    increases, p = 0.001, n = 466

    Heart failure | 5.25 (2.61–10.58) | < 0.001 | 3.85 (1.83–8.12) | < 0.001

    PMID 40890448 · one of two readings recorded this

  • Baseline QT prolongation, heart failure

    increases, p = 0.001, n = 466

    Heart failure | 5.25 (2.61–10.58) | < 0.001 | 3.85 (1.83–8.12) | < 0.001

    PMID 40890448 · one of two readings recorded this

  • Baseline QT prolongation, LVDd

    increases, p = 0.001, n = 466

    LVDd | 1.19 (1.12–1.26) | < 0.001 | -- | --

    PMID 40890448 · one of two readings recorded this

The whole record — 251 rows